{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AS+MDI&page=5",
    "query": {
      "intervention": "AS MDI",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 127,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AS+MDI&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=AS+MDI&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T04:40:58.649Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02196714",
      "title": "PK Study of PT003 and PT001 in Japanese Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "Glycopyrronium and Formoterol Fumarate (GFF) Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium and Formoterol Fumarate (GFF) Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium (GP) Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Glycopyrronium (GP) Dose 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-10-22T04:40:58.649Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02196714"
    },
    {
      "nct_id": "NCT01306214",
      "title": "Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BI 10773",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 566,
      "start_date": "2011-02",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2014-06-17",
      "last_synced_at": "2026-10-22T04:40:58.649Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "El Cajon",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01306214"
    },
    {
      "nct_id": "NCT06411548",
      "title": "InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "InsuLearn",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2025-03-27",
      "completion_date": "2025-10-17",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-10-22T04:40:58.649Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06411548"
    },
    {
      "nct_id": "NCT06792175",
      "title": "Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Autism Spectrum Disorder",
        "Depression - Major Depressive Disorder",
        "Anxiety, Generalized",
        "Bipolar Disorder (BD)",
        "Attention Deficit Hyperactivity Disorder (ADHD)",
        "Schizophrenia Spectrum &Amp; Other Psychotic Disorders",
        "Post Traumatic Stress Disorder",
        "Obsessive Compulsive Disorder (OCD)"
      ],
      "interventions": [
        {
          "name": "Solicue Machine Learning Models",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Mercuria Machine Learning Models",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Psyrin Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "13 Years to 60 Years"
      },
      "enrollment_count": 500,
      "start_date": "2025-02-04",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2025-09-03",
      "last_synced_at": "2026-10-22T04:40:58.649Z",
      "location_count": 2,
      "location_summary": "Brookline, Massachusetts • Zanesville, Ohio",
      "locations": [
        {
          "city": "Brookline",
          "state": "Massachusetts"
        },
        {
          "city": "Zanesville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06792175"
    },
    {
      "nct_id": "NCT02654145",
      "title": "Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Mepolizumab 100mg SC",
          "type": "DRUG"
        },
        {
          "name": "Albuterol/salbutamol MDIs",
          "type": "DRUG"
        },
        {
          "name": "Omalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2016-03-17",
      "completion_date": "2017-05-31",
      "has_results": true,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-10-22T04:40:58.649Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Riverside, California • Roseville, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02654145"
    },
    {
      "nct_id": "NCT03012061",
      "title": "Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "UMEC",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Furoate",
          "type": "DRUG"
        },
        {
          "name": "Albuterol/salbutamol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 425,
      "start_date": "2017-01-25",
      "completion_date": "2018-05-30",
      "has_results": true,
      "last_update_posted_date": "2020-10-28",
      "last_synced_at": "2026-10-22T04:40:58.649Z",
      "location_count": 19,
      "location_summary": "Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        },
        {
          "city": "Natchitoches",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03012061"
    },
    {
      "nct_id": "NCT05967260",
      "title": "DailyDose Smart Snack Study for T1D on MDI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus With Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "DailyDose Smart Snack app",
          "type": "DEVICE"
        },
        {
          "name": "Dexcom G6 CGM",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 21,
      "start_date": "2023-09-01",
      "completion_date": "2024-09-20",
      "has_results": true,
      "last_update_posted_date": "2025-05-31",
      "last_synced_at": "2026-10-22T04:40:58.649Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05967260"
    },
    {
      "nct_id": "NCT01479621",
      "title": "A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fp MDPI",
          "type": "DRUG"
        },
        {
          "name": "Flovent Diskus",
          "type": "DRUG"
        },
        {
          "name": "albuterol/salbutamol",
          "type": "DRUG"
        },
        {
          "name": "Placebo MDPI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 909,
      "start_date": "2012-01",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2017-06-05",
      "last_synced_at": "2026-10-22T04:40:58.649Z",
      "location_count": 129,
      "location_summary": "Homewood, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 104 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01479621"
    },
    {
      "nct_id": "NCT01899144",
      "title": "Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Albuterol Spiromax",
          "type": "DRUG"
        },
        {
          "name": "ProAir HFA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "4 Years to 11 Years"
      },
      "enrollment_count": 61,
      "start_date": "2013-07",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2022-01-26",
      "last_synced_at": "2026-10-22T04:40:58.649Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Alaska"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01899144"
    },
    {
      "nct_id": "NCT01349816",
      "title": "PT003 MDI Dose Confirmation Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "PT003",
          "type": "DRUG"
        },
        {
          "name": "PT001",
          "type": "DRUG"
        },
        {
          "name": "PT005",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 185,
      "start_date": "2011-06",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2017-04-27",
      "last_synced_at": "2026-10-22T04:40:58.649Z",
      "location_count": 13,
      "location_summary": "Rancho Mirage, California • Colorado Springs, Colorado • Waterbury, Connecticut + 10 more",
      "locations": [
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01349816"
    }
  ]
}